Effect of Oxandrolone and Timing of Oral Ethinylestradiol Initiation on Pubertal Progression, Height Velocity and Bone Maturation in the UK Turner Study

Rebecca Perry, Emma Jane Gault, Wendy F. Paterson, David B. Dunger, Malcolm Donaldson

Hormone Research in Paediatrics · 2014 · 17 citations · 41 references

Concepts

Abstract

<b><i>Background:</i></b> A UK study showed final height in Turner syndrome (TS) girls receiving growth hormone is affected by age at pubertal induction and oxandrolone (Ox). Using data from that study, we analysed the effect of timing of oral ethinylestradiol (EE<sub>2</sub>) and Ox on height velocity (HV), bone maturation and pubertal progression, and compared growth response in EE<sub>2</sub>-treated versus spontaneous puberty. <b><i>Methods:</i></b> Analysis of HV, bone age and pubertal stage in 92 TS girls (7-13 years) randomised to Ox (0.05 mg/kg/day; max: 2.5 mg/day) or placebo from 9 years, and EE<sub>2</sub> (year 1: 2 µg/day; year 2: 4 µg/day; year 3: 6/8/10 µg/day × 4 months) or placebo at 12 years with EE<sub>2</sub> at 14 years. Girls enrolled at >12.25 years received EE<sub>2</sub> at 14 years (‘late group'). <b><i>Results:</i></b> Fifty-six girls were randomised to EE<sub>2</sub> at 12 years (n = 28, 11 Ox) or 14 years (n = 28, 13 Ox); there were 19 girls in the late group (9 Ox) and 17 girls with spontaneous puberty (10 Ox). Girls receiving EE<sub>2</sub> at 12 versus 14 years had faster bone maturation, but neither group showed acceleration. Ox increased HV without altering bone maturation or pubertal progression. Girls with spontaneous puberty had greater pubertal growth (mean PHV 8.5 cm/year; p < 0.001) and height gain (p < 0.001) than EE<sub>2</sub>-treated girls despite similar mean enrolment height SD and dysmorphology scores. <b><i>Conclusion:</i></b> Pubertal induction with EE<sub>2</sub> does not replicate the acceleration observed in unaffected girls or TS girls with spontaneous puberty.

References

41